Navigation Links
Osseon Receives Patent Allowance for Novel Spinal VCF Treatment Devices
Date:7/14/2010

SANTA ROSA, Calif., July 14 /PRNewswire/ -- Osseon Therapeutics, Inc., a biomedical device company based in Santa Rosa, California, today received a notice of allowance for its spinal vertebral compression fracture (VCF) technology. The company which was started in 2006 has thirteen additional patent applications pending in the United States and throughout the world for related spinal therapies and devices. The lead inventor for this inaugural patent is Dr. Y. King Liu, one of three founders of Osseon.

The company has been marketing its FDA approved first generation "Osseoplasty™" systems since February, 2009. The Osseon devices received CE Mark in November 2009 and the company began marketing the product line in Europe in February of 2010. The proprietary Osseoplasty™ procedure has been performed in over 900 patients in the U.S. and Europe.

According to John Stalcup, Ph.D., CEO of Osseon, "This initial patent allowance for Osseon's spinal VCF technology is a major milestone for the company's intellectual property pursuits. We anticipate receiving a number of additional patents in the future on various aspects of the Osseoflex™ steerable and curvable needle and the novel methods for bone cement delivery, which enable a safe, effective, and minimally invasive approach for spine disease treatment."

About Osseon

Osseon Therapeutics, Inc. is focused on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease.  Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the lower portion of the thoracic and the entire lumbar vertebral spine, Osseon offers relief to those suffering from these maladies, as well as the physicians and medical facilities that treat them.  Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union.  For more information, visit our web site at www.osseon.com.


'/>"/>
SOURCE Osseon Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Osseon Launches in Europe
2. Osseon Therapeutics Demonstrates to the European Medical Community How to Think Outside The Balloon When Treating Vertebral Compression Fractures
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. CryoCor Receives FDA Approval for Right Atrial Flutter
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
11. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ) today ... R. Goodwin , U.S. District Court Judge for the ... entered a case management order in MDL 2325, American ... (the "MDL") that includes a provision requiring plaintiffs in ... specific causation within one hundred twenty (120) days of ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... Genes ... for medications in select Florida and Texas doctors' offices and clinics. This breakthrough ... application of genetic testing recognizes the role genes play in determining an individual's ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. Mitchell Mehlman and ... in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine and emergency dental ... dentist fit into their patients’ busy lifestyles. Dental365 also gladly work with most ...
(Date:6/24/2017)... ... ... Doorknobs are for convenience, deadbolts are for security. , There are many ways ... alarm system installed. But unless there is a working deadbolt lock that is used ... Locksmith in Killeen, TX says: “In the majority of home burglaries, intruders use force ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... what is needed and will ultimately do significant harm to people with all ... everyone. , "While it leaves in place the Affordable Care Act (ACA) ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... (BCRA), their proposed healthcare bill to repeal and replace the Affordable Care Act ... bill would make significant cuts to Medicaid, a public health insurance program for ...
Breaking Medicine News(10 mins):